GILDAGIA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GILDAGIA (GILDAGIA).
GILDAGIA (lixisenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, increasing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
| Metabolism | Metabolized by proteolytic degradation via multiple enzymes (including DPP-4, neutral endopeptidases, and others). No significant CYP450 involvement. |
| Excretion | Primarily hepatic metabolism; renal excretion of unchanged drug is minimal (<1%). Biliary/fecal excretion accounts for ~85% of the administered dose, with the remainder as metabolites in urine. |
| Half-life | Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in healthy volunteers, allowing once-daily dosing. |
| Protein binding | ~99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 50-60 L (0.7-0.9 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 50% (range 30-70%), with significant first-pass metabolism. |
| Onset of Action | Oral: Peak plasma concentration reached within 2-4 hours; clinical effect (e.g., reduction in uric acid) observed within 2-4 weeks of continuous dosing. |
| Duration of Action | Duration of action is approximately 24 hours, supporting once-daily dosing. Steady-state achieved in 5-7 days. |
20 mg orally once daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For ESRD (GFR <15 mL/min) or on dialysis, maximum dose is 10 mg orally once daily. Not recommended in severe renal impairment (GFR 15-29 mL/min) due to limited data. |
| Liver impairment | Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose to 10 mg orally once daily. Child-Pugh class C: not recommended. |
| Pediatric use | Weight <20 kg: 0.4 mg/kg orally once daily (max 10 mg). Weight 20-40 kg: 10 mg orally once daily. Weight >40 kg: 20 mg orally once daily. |
| Geriatric use | No specific dose adjustment; monitor renal function and volume status due to increased risk of hypotension and electrolyte disturbances. Initiate at 10 mg orally once daily in patients aged ≥75 years if clinically appropriate. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GILDAGIA (GILDAGIA).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Due to potential for hypoglycemia in nursing infant, avoid breastfeeding during therapy until more data available. |
| Teratogenic Risk | No adequate human data; animal studies show increased fetal resorptions and reduced fetal weight at maternal toxic doses. Risk cannot be excluded (Category C). First trimester: consider alternative therapy unless benefit outweighs risk. Second/third trimester: limited data; potential for fetal hypoglycemia if maternal glucose levels drop excessively. |
■ FDA Black Box Warning
None
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma or MEN-2.","History of severe hypersensitivity (e.g., anaphylaxis, angioedema) to lixisenatide or any component.","Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease.","Type 1 diabetes mellitus or diabetic ketoacidosis."]
| Precautions | ["Risk of acute pancreatitis: discontinue if suspected.","History of thyroid C-cell tumors: contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN-2.","Hypoglycemia: increased risk when used with insulin or sulfonylureas.","Renal impairment: not recommended in severe renal impairment (CrCl <30 mL/min).","Gastrointestinal effects: nausea, vomiting, diarrhea may occur; may worsen gallbladder disease.","Immunogenicity: may develop anti-drug antibodies; rarely associated with injection site reactions."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose closely to avoid hypoglycemia. Fetal ultrasound monitoring for growth and anatomy if exposed during first trimester. Consider monitoring for fetal hypoglycemia (e.g., nonstress test, biophysical profile) in third trimester if maternal glucose poorly controlled. |
| Fertility Effects | No specific human data; animal studies show no impairment of fertility at therapeutic doses. Theoretical risk from metabolic effects on reproductive hormones, but not documented. |